ChemoCentryx, Inc.
CCXI announced that GlaxoSmithKline GSK has returned to
ChemoCentryx all rights to vercirnon (also known as Traficet-EN and CCX282),
an inhibitor of the chemokine receptor known as CCR9, for all indications,
including the treatment of inflammatory bowel disease.
"We are pleased to have a response from GSK which gives us certainty that
vercirnon now returns entirely to ChemoCentryx, and which confers to us many
degrees of freedom in deciding this valuable asset's forward path," stated
Thomas J. Schall, PhD, President and Chief Executive Officer ChemoCentryx.
"Importantly, in addition to regaining rights to the compound, the full data
set amassed on all the trials (whether concluded or not) will be transferred
to ChemoCentryx. Such data will allow us to assess, alone or potentially with
a partner, a remaining, critical clinical trial question: that is, whether the
drug maintains remission in Crohn's disease, as we saw in the maintenance
phase of the previously conducted PROTECT-1 trial."
In August 2006, ChemoCentryx and GSK entered into a worldwide strategic
alliance of which vercirnon was a part. Two other development programs remain
under the alliance: CCX354, an inhibitor of the chemokine receptor known as
CCR1 for the treatment of rheumatoid arthritis for which GSK exercised its
option for an exclusive license in 2011 and CCX168, an inhibitor of the
complement receptor C5a, currently in Phase II development for ANCA
vasculitis.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in